安序源科技递表港交所 2025年上半年亏损516万美元

Core Viewpoint - Axbio International Limited has submitted an application for listing on the Hong Kong Stock Exchange, with CICC and Puyin International as joint sponsors [1][2] Company Overview - Axbio International Limited was established in 2016 and focuses on the development and commercialization of molecular diagnostic instruments and biochips, holding a leading position in this field [1] - The company's product portfolio includes a microarray chip analyzer, two EL-NGS gene sequencers, and various supporting test kits, all of which are self-developed [1] - The core product, AxiLonaEL-100, is one of the few molecular diagnostic products in China capable of electrochemical, multi-target, rapid, low-cost, and integrated biomolecular detection [1] Product Details - AxiLonaEL-100 currently supports nucleic acid testing and plans to expand its capabilities to include both nucleic acid and protein detection in the future [1] - The EL-100 performs qualitative analysis of signals generated by nucleic acid microarray chips to support nucleic acid-based medical testing applications, but does not conduct absolute quantification of nucleic acid samples [1] Financial Performance - Axbio International Limited reported no revenue in 2023, with projected revenue of $479,000 in 2024 [2] - The company incurred losses of $22.856 million, $23.466 million, and $5.155 million for the years ending June 30 in 2023, 2024, and 2025, respectively [2] - Adjusted net losses were $19.676 million, $14.658 million, and $5.976 million for the same periods [2]